



- (51) **International Patent Classification:**  
*A61K 35/15* (2015.01) *C12N 5/00* (2006.01)
- (21) **International Application Number:**  
PCT/SG2024/050115
- (22) **International Filing Date:**  
28 February 2024 (28.02.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
10202300541U 28 February 2023 (28.02.2023) SG
- (71) **Applicants:** **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). **SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 10 Hospital Boulevard, #19-01 Outram Community Hospital, Singapore 168582 (SG).
- (72) **Inventor:** **TEO (ZHANG), Wan Yee (Wanyi)**; 61 Biopolis Dr, Proteos, Singapore 138673 (SG).
- (74) **Agent:** **DONALDSON & BURKINSHAW LLP**; P.O. Box 3667, Robinson Road Post Office, Singapore 905667 (SG).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**  
— of inventorship (Rule 4.17(iv))

(54) **Title:** IMMUNE CELL-DERIVED SECRETOME

## Generation of Secretome




FIG. 2A

(57) **Abstract:** There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.

[Continued on next page]

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*